LLY vs BIIB
By Alex · Tickerpine
Eli Lilly and Company vs Biogen Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | BIIB |
|---|---|---|
| Price | $1,220.28 | $208.87 |
| Market cap | $1.09T | $30.86B |
| P/E ratio | 41.0 | 36.3 |
| ROE | 102.29% | 4.58% |
| Profit margin | 33.53% | 8.32% |
| Revenue growth | 47.70% | 3.40% |
| Dividend yield | 0.57% | — |
| Beta | 0.51 | 0.16 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs BIIB in plain English
- LLY is the bigger company — about 35.3× the market cap of BIIB.
- BIIB is cheaper on earnings (P/E 36.3 vs 41.0).
- LLY earns a higher return on equity (102% vs 5%).
- LLY is growing revenue faster (48% vs 3%).
- LLY pays a dividend (0.57%) while the other effectively doesn't.
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
BIIB return calculator
See what $1,000 in Biogen Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.